Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Fly Intel: Top five analyst initiations » 09:55
11/05/20
11/05
09:55
11/05/20
09:55
PAVM

PAVmed

$1.86 /

+0.04 (+2.20%)

, OCFT

OneConnect

$22.37 /

+0.37 (+1.68%)

, RLAY

Relay Therapeutics

$38.70 /

+ (+0.00%)

, CSWC

Capital Southwest

$15.21 /

-0.03 (-0.20%)

, ATNM

Actinium Pharmaceuticals

$11.92 /

+0.65 (+5.77%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PAVmed (PAVM) initiated with a Buy at Ascendiant. 2. OneConnect (OCFT) initiated with a Buy at Citi. 3. Relay Therapeutics (RLAY) initiated with a Buy at H.C. Wainwright. 4. Capital Southwest (CSWC) resumed with an Outperform at JMP Securities. 5. Actinium Pharmaceuticals (ATNM) initiated with a Buy at Alliance Global Partners. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
RLAY Relay Therapeutics
$38.70 /

+ (+0.00%)

PAVM PAVmed
$1.86 /

+0.04 (+2.20%)

CSWC Capital Southwest
$15.21 /

-0.03 (-0.20%)

ATNM Actinium Pharmaceuticals
$11.92 /

+0.65 (+5.77%)

PAVM PAVmed
$1.86 /

+0.04 (+2.20%)

11/05/20 Ascendiant
Ascendiant starts PAVmed with Buy on carpal tunnel potential
11/05/20 Ascendiant
PAVmed initiated with a Buy at Ascendiant
10/13/20 Lake Street
PAVmed initiated with a Buy at Lake Street
OCFT OneConnect
$22.37 /

+0.37 (+1.68%)

11/05/20 Citi
OneConnect initiated with a Buy at Citi
07/21/20 JPMorgan
OneConnect downgraded to Neutral from Overweight at JPMorgan
06/23/20 KeyBanc
OneConnect price target raised to $22 from $14 at KeyBanc
02/21/20 Goldman Sachs
OneConnect downgraded to Neutral from Buy at Goldman Sachs
RLAY Relay Therapeutics
$38.70 /

+ (+0.00%)

11/05/20 H.C. Wainwright
Relay Therapeutics initiated with a Buy at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
08/10/20
Fly Intel: Top five analyst initiations
08/10/20 Guggenheim
Relay Therapeutics initiated with a Buy at Guggenheim
CSWC Capital Southwest
$15.21 /

-0.03 (-0.20%)

11/05/20 JMP Securities
Capital Southwest resumed with an Outperform at JMP Securities
06/04/20 JMP Securities
Capital Southwest price target lowered to $17 from $22.50 at JMP Securities
03/17/20 National Securities
Capital Southwest upgraded to Buy from Neutral at National Securities
03/03/20 National Securities
Capital Southwest downgraded to Neutral from Buy at National Securities
ATNM Actinium Pharmaceuticals
$11.92 /

+0.65 (+5.77%)

11/05/20 Alliance Global Partners
Actinium Pharmaceuticals initiated with a Buy at Alliance Global Partners
11/04/20 H.C. Wainwright
Actinium ASH abstract 'impresses,' says H.C. Wainwright
09/21/20 JonesTrading
Actinium Pharmaceuticals transferred with a Buy at JonesTrading
06/04/20 H.C. Wainwright
Actinium Pharmaceuticals initiated with a Buy at H.C. Wainwright
RLAY Relay Therapeutics
$38.70 /

+ (+0.00%)

OCFT OneConnect
$22.37 /

+0.37 (+1.68%)

CSWC Capital Southwest
$15.21 /

-0.03 (-0.20%)

  • 13
    Aug
  • 16
    Jul
  • 17
    Jun
  • 22
    Apr
  • 13
    Dec
RLAY Relay Therapeutics
$38.70 /

+ (+0.00%)

CSWC Capital Southwest
$15.21 /

-0.03 (-0.20%)

OCFT OneConnect
$22.37 /

+0.37 (+1.68%)

CSWC Capital Southwest
$15.21 /

-0.03 (-0.20%)

ATNM Actinium Pharmaceuticals
$11.92 /

+0.65 (+5.77%)

Initiation
Actinium Pharmaceuticals initiated with a Buy at Alliance Global Partners » 08:55
11/05/20
11/05
08:55
11/05/20
08:55
ATNM

Actinium Pharmaceuticals

$11.27 /

+1.05 (+10.27%)

Alliance Global Partners…

Alliance Global Partners analyst Matt Cross initiated coverage of Actinium Pharmaceuticals with a Buy rating and $25 price target.

ShowHide Related Items >><<
ATNM Actinium Pharmaceuticals
$11.27 /

+1.05 (+10.27%)

ATNM Actinium Pharmaceuticals
$11.27 /

+1.05 (+10.27%)

11/04/20 H.C. Wainwright
Actinium ASH abstract 'impresses,' says H.C. Wainwright
09/21/20 JonesTrading
Actinium Pharmaceuticals transferred with a Buy at JonesTrading
06/04/20 H.C. Wainwright
Actinium Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/17/20 JonesTrading
Key Actinium questions could be answered sooner than expected, says JonesTrading
  • 17
    Jun
  • 22
    Apr
ATNM Actinium Pharmaceuticals
$11.27 /

+1.05 (+10.27%)

Over a month ago
Hot Stocks
Actinium reports 100% remission rate in third dose cohort of Phase 1 trial » 12:23
11/04/20
11/04
12:23
11/04/20
12:23
ATNM

Actinium Pharmaceuticals

$10.82 /

+0.6 (+5.87%)

Actinium Pharmaceuticals…

Actinium Pharmaceuticals announced that 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisconsin achieved remission. Across all three cohorts, 67% or 10/15 patients treated with 0.25, 0.50 and 0.75 uCi/kg of Actimab-A and the standard regimen of CLAG-M achieved a Complete Remission or Complete Remission with inadequate hematopoietic recovery. Further, 83% of patients who received 3 or fewer prior lines of treatment achieved CR or CRi. Notably, 70% of CR/CRi patients were MRD negative indicating a deep remission with no detectable disease. These results which include subtherapeutic doses of Actimab-A in the first two dose cohorts and represent a marked improvement over CLAG-M treatment alone implying potential mechanistic synergy. This novel Phase 1 combination trial is for patients with relapsed or refractory acute myeloid leukemia age 18 and above deemed medically fit for cytotoxic chemotherapy. This data has been accepted for oral presentation at the 2020 American Society of Hematology annual meeting that is being held virtually December 5-8, 2020.

ShowHide Related Items >><<
ATNM Actinium Pharmaceuticals
$10.82 /

+0.6 (+5.87%)

ATNM Actinium Pharmaceuticals
$10.82 /

+0.6 (+5.87%)

11/04/20 H.C. Wainwright
Actinium ASH abstract 'impresses,' says H.C. Wainwright
09/21/20 JonesTrading
Actinium Pharmaceuticals transferred with a Buy at JonesTrading
06/04/20 H.C. Wainwright
Actinium Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/17/20 JonesTrading
Key Actinium questions could be answered sooner than expected, says JonesTrading
  • 17
    Jun
  • 22
    Apr
ATNM Actinium Pharmaceuticals
$10.82 /

+0.6 (+5.87%)

Hot Stocks
Actinium's Actimab-A venetoclax data accepted for poster presentation at ASH » 12:02
11/04/20
11/04
12:02
11/04/20
12:02
ATNM

Actinium Pharmaceuticals

$10.87 /

+0.65 (+6.36%)

Actinium Pharmaceuticals…

Actinium Pharmaceuticals announced that data from the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial, has been accepted for poster presentation at the 2020 American Society of Hematology annual meeting that is being held virtually December 5-8, 2020. Data highlights include: Combining Actimab-A with venetoclax in patients with R/R AML has an acceptable initial clinical safety profile at the initial subtherapeutic dose level of 0.5 muCi/kg of Actimab-A. A partial response was observed after a single cycle of Actimab-A and venetoclax. Three R/R AML patients with a median age of 54 years have been enrolled to date. The enrolled patients had a median of 2 therapies and a median bone marrow blast percentage of 30%. All 3 patients had poor risk with adverse cytogenetics, and each patient has an additional high-risk marker.

ShowHide Related Items >><<
ATNM Actinium Pharmaceuticals
$10.87 /

+0.65 (+6.36%)

ATNM Actinium Pharmaceuticals
$10.87 /

+0.65 (+6.36%)

11/04/20 H.C. Wainwright
Actinium ASH abstract 'impresses,' says H.C. Wainwright
09/21/20 JonesTrading
Actinium Pharmaceuticals transferred with a Buy at JonesTrading
06/04/20 H.C. Wainwright
Actinium Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/17/20 JonesTrading
Key Actinium questions could be answered sooner than expected, says JonesTrading
  • 17
    Jun
  • 22
    Apr
ATNM Actinium Pharmaceuticals
$10.87 /

+0.65 (+6.36%)

Recommendations
Actinium ASH abstract 'impresses,' says H.C. Wainwright » 11:33
11/04/20
11/04
11:33
11/04/20
11:33
ATNM

Actinium Pharmaceuticals

$10.76 /

+0.54 (+5.28%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis noted that abstracts for the upcoming American Society of Hematology, or ASH, annual meeting were inadvertently released a day early and and the medical organization decided to leave them up. Because of this, updated data from the ongoing Phase 1 trial of Actimab-A-+ in r/r AML patients is available and the abstract "impresses," Pantginis said. In cohort 3, all three patients achieved remission, noted Pantginis, who added that this study "represents an important opportunity to offer a meaningful option to r/r AML patients who are medically fit and a bridge to allogeneic transplant." He has a Buy rating and $65 price target on Actinium Pharmaceuticals shares.

ShowHide Related Items >><<
ATNM Actinium Pharmaceuticals
$10.76 /

+0.54 (+5.28%)

ATNM Actinium Pharmaceuticals
$10.76 /

+0.54 (+5.28%)

09/21/20 JonesTrading
Actinium Pharmaceuticals transferred with a Buy at JonesTrading
06/04/20 H.C. Wainwright
Actinium Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/17/20 JonesTrading
Key Actinium questions could be answered sooner than expected, says JonesTrading
  • 17
    Jun
  • 22
    Apr
ATNM Actinium Pharmaceuticals
$10.76 /

+0.54 (+5.28%)

Hot Stocks
Actinium Pharmaceuticals sees cash sufficient to complete current trials » 07:26
10/28/20
10/28
07:26
10/28/20
07:26
ATNM

Actinium Pharmaceuticals

$10.95 /

-0.54 (-4.70%)

Actinium reported a cash…

Actinium reported a cash balance of $48.2M as of September 30 vs. $9.2M as of December 31, 2019 and a net loss of $5.5M for 3Q:2020. Based on current estimates, the current cash balance is expected to fund operations through clinical milestones including completion of the Pivotal Phase 3 SIERRA trial, completion of ongoing Phase 1/2 Actimab-A combination trials and planned R&D activity.

ShowHide Related Items >><<
ATNM Actinium Pharmaceuticals
$10.95 /

-0.54 (-4.70%)

ATNM Actinium Pharmaceuticals
$10.95 /

-0.54 (-4.70%)

09/21/20 JonesTrading
Actinium Pharmaceuticals transferred with a Buy at JonesTrading
06/04/20 H.C. Wainwright
Actinium Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/17/20 JonesTrading
Key Actinium questions could be answered sooner than expected, says JonesTrading
  • 17
    Jun
  • 22
    Apr
ATNM Actinium Pharmaceuticals
$10.95 /

-0.54 (-4.70%)

Conference/Events
Actinium Pharmaceuticals to host conference call » 07:25
10/22/20
10/22
07:25
10/22/20
07:25
ATNM

Actinium Pharmaceuticals

$11.84 /

+0.89 (+8.13%)

Conference call to…

Conference call to provide an update on the Iomab-ACT program will be held on October 22 at 8 am. Webcast Link

ShowHide Related Items >><<
ATNM Actinium Pharmaceuticals
$11.84 /

+0.89 (+8.13%)

ATNM Actinium Pharmaceuticals
$11.84 /

+0.89 (+8.13%)

09/21/20 JonesTrading
Actinium Pharmaceuticals transferred with a Buy at JonesTrading
06/04/20 H.C. Wainwright
Actinium Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/17/20 JonesTrading
Key Actinium questions could be answered sooner than expected, says JonesTrading
  • 17
    Jun
  • 22
    Apr
ATNM Actinium Pharmaceuticals
$11.84 /

+0.89 (+8.13%)

Conference/Events
Actinium Pharmaceuticals to host conference call » 04:55
10/22/20
10/22
04:55
10/22/20
04:55
ATNM

Actinium Pharmaceuticals

$11.84 /

+0.89 (+8.13%)

Conference call to…

Conference call to provide an update on the Iomab-ACT program will be held on October 22 at 8 am. Webcast Link

ShowHide Related Items >><<
ATNM Actinium Pharmaceuticals
$11.84 /

+0.89 (+8.13%)

ATNM Actinium Pharmaceuticals
$11.84 /

+0.89 (+8.13%)

09/21/20 JonesTrading
Actinium Pharmaceuticals transferred with a Buy at JonesTrading
06/04/20 H.C. Wainwright
Actinium Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/17/20 JonesTrading
Key Actinium questions could be answered sooner than expected, says JonesTrading
  • 17
    Jun
  • 22
    Apr
ATNM Actinium Pharmaceuticals
$11.84 /

+0.89 (+8.13%)

Conference/Events
Actinium Pharmaceuticals to host conference call » 07:50
10/21/20
10/21
07:50
10/21/20
07:50
ATNM

Actinium Pharmaceuticals

$10.95 /

-0.6 (-5.19%)

Conference call to…

Conference call to provide an update on the Iomab-ACT program will be held on October 22 at 8 am. Webcast Link

ShowHide Related Items >><<
ATNM Actinium Pharmaceuticals
$10.95 /

-0.6 (-5.19%)

ATNM Actinium Pharmaceuticals
$10.95 /

-0.6 (-5.19%)

09/21/20 JonesTrading
Actinium Pharmaceuticals transferred with a Buy at JonesTrading
06/04/20 H.C. Wainwright
Actinium Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/17/20 JonesTrading
Key Actinium questions could be answered sooner than expected, says JonesTrading
  • 17
    Jun
  • 22
    Apr
ATNM Actinium Pharmaceuticals
$10.95 /

-0.6 (-5.19%)

Hot Stocks
Actinium Pharmaceuticals awarded grant by NIH to study Iomab-ACT » 07:06
10/21/20
10/21
07:06
10/21/20
07:06
ATNM

Actinium Pharmaceuticals

$10.95 /

-0.6 (-5.19%)

Actinium Pharmaceuticals…

Actinium Pharmaceuticals has been awarded a Small Business Technology Transfer grant by the National Institutes of Health to support a clinical collaboration with Memorial Sloan Kettering Cancer Center to study Iomab-ACT, Actinium's CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. The CD19 CAR-T has been previously studied by MSK in a Phase 2 trial with chemotherapy conditioning in patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. MSK will lead this first of its kind study to utilize targeted radiopharmaceutical ARC-based lymphodepletion to replace chemotherapy-based conditioning prior to CAR T-cell therapy. The study will assess the feasibility of using Iomab-ACT targeted lymphodepletion prior to MSK's 19-28z CAR-T and assess safety and efficacy outcomes relative to results with MSK's CAR-T 19-28z in patients who had received chemotherapy-based lymphodepletion prior to CAR-T administration. Results published in the New England Journal of Medicine with MSK's 19-28z CD19 CAR-T in 53 patients with R/R B-ALL reported complete remissions in 83% of patients.

ShowHide Related Items >><<
ATNM Actinium Pharmaceuticals
$10.95 /

-0.6 (-5.19%)

ATNM Actinium Pharmaceuticals
$10.95 /

-0.6 (-5.19%)

09/21/20 JonesTrading
Actinium Pharmaceuticals transferred with a Buy at JonesTrading
06/04/20 H.C. Wainwright
Actinium Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/17/20 JonesTrading
Key Actinium questions could be answered sooner than expected, says JonesTrading
  • 17
    Jun
  • 22
    Apr
ATNM Actinium Pharmaceuticals
$10.95 /

-0.6 (-5.19%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.